why choose us

First received: November 27, 2023

Clinical Trial: ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Ovarian Cancer

Study Type: INTERVENTIONAL


Official Title: Phase l Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Brief Summary: This Phase I, open label, dose determining study of oral niraparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with metastatic or recurrent solid cancer.Dose escalation will follow the mTPI-2/Keyboard design.Eligible patients will receive therapy until disease progression or unacceptable toxicities are experienced.

Read more